BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 31825756)

  • 1. Oncologic Implications of Chronic Hepatitis C Virus Infection.
    Hwang JP; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Torres HA; Bailey HH
    J Oncol Pract; 2019 Dec; 15(12):629-637. PubMed ID: 31825756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma and non-Hodgkin lymphoma in a patient with chronic hepatitis C and cirrhosis.
    Suriawinata A; Ye MQ; Emre S; Strauchen J; Thung SN
    Arch Pathol Lab Med; 2000 Oct; 124(10):1532-4. PubMed ID: 11035591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
    Masarone M; Persico M
    Expert Rev Anti Infect Ther; 2011 May; 9(5):535-43. PubMed ID: 21609265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
    Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
    Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
    J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
    Allaire M; Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; DI Martino V; Sutton A; Letouzé E; Audureau E; Roudot-Thoraval F;
    Hepatology; 2018 Oct; 68(4):1245-1259. PubMed ID: 29663511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and natural history of hepatitis C virus infection among children and young people.
    Modin L; Arshad A; Wilkes B; Benselin J; Lloyd C; Irving WL; Kelly DA
    J Hepatol; 2019 Mar; 70(3):371-378. PubMed ID: 30496763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
    Ueno Y; Sollano JD; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
    Bird SM; Goldberg DJ; Hutchinson SJ
    J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
    Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study.
    Nam JY; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Bae SH; Ki M; Choi HY; Lee EY; Jeong SH
    Gut Liver; 2020 Mar; 14(2):207-217. PubMed ID: 31158950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France.
    Larsen C; Bousquet V; Delarocque-Astagneau E; Pioche C; Roudot-Thoraval F; ; ; Desenclos JC
    J Med Virol; 2010 Oct; 82(10):1647-54. PubMed ID: 20827760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
    Tholey DM; Ahn J
    Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
    Ikeda K; Marusawa H; Osaki Y; Nakamura T; Kitajima N; Yamashita Y; Kudo M; Sato T; Chiba T
    Ann Intern Med; 2007 May; 146(9):649-56. PubMed ID: 17470833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.